155 filings
Page 3 of 8
8-K
9pilvy 1n1r
4 Mar 20
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
4:08pm
8-K
pbfo lxz8gznkg
18 Feb 20
Other Events
8:47am
8-K
81f53 30yb90
17 Jan 20
Other Events
5:06pm
8-K
vk8t2y
9 Jan 20
Other Events
4:04pm
8-K
pwrqp1yp0f2 0mf4
8 Jan 20
Departure of Directors or Certain Officers
4:11pm
8-K
39wx4p9aakqswys0kt
14 Nov 19
Entry into a Material Definitive Agreement
4:27pm
8-K
jejei5hd42ij7nl kzaj
12 Nov 19
Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
4:06pm
8-K
4uvm89h7lfg64suzkchu
8 Aug 19
Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
4:05pm
8-K
py5 tak40q
11 Jul 19
Amendments to Articles of Incorporation or Bylaws
4:54pm
8-K
8iiwdm
13 Jun 19
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
mff2eihottofict5y
9 May 19
Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:13pm
8-K
9a6tka8wmxp2c esmer4
9 Apr 19
Other Events
4:58pm
8-K
348e2eqmn7lcvrphc
21 Mar 19
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
4:10pm
8-K
errq c6zf8clixh
21 Feb 19
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
4:08pm
8-K
iqf2xx
17 Jan 19
Departure of Directors or Certain Officers
4:16pm
8-K
vpet5clhsj2usn5e9e1y
4 Jan 19
Departure of Directors or Certain Officers
4:29pm
8-K
r8fcv6o9
28 Dec 18
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
4:01pm
8-K/A
v8q3e 27xz1b2avcu0
4 Dec 18
Financial Statements and Exhibits
4:02pm
8-K
ehk5n
7 Nov 18
Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
4:10pm
8-K
izlryq
2 Nov 18
Departure of Directors or Certain Officers
4:05pm